Literature DB >> 12803320

Cross-presentation of antigens by dendritic cells.

Gabrielle T Belz1, Francis R Carbone, William R Heath.   

Abstract

T lymphocytes recognize antigen presented on the surface of antigen-presenting cells byMHC class I and class II molecules. Classically, MHC class I molecules present self- or pathogen-derived antigens that are synthesized within the cell, whereas exogenous antigens derived via endocytic uptake are loaded onto MHC class II molecules for presentation to CD4+ T cells. It is becoming increasingly clear that some dendritic cells are also specialized to process exogenous antigens into the MHC class I pathway for presentation to CD8+ T cells. This process is known as cross-presentation. It provides a mechanism that can drive dendritic cells to generate either tolerance to self-antigens or immunity to pathogens. The cells responsible for, and mechanisms underlying, this decision between tolerance and immunity via cross-presentation has become the focus of intense study to determine how various dendritic cell subsets effect the different outcomes.

Mesh:

Substances:

Year:  2002        PMID: 12803320

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  11 in total

1.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Modeling of influenza-specific CD8+ T cells during the primary response indicates that the spleen is a major source of effectors.

Authors:  Hulin Wu; Arun Kumar; Hongyu Miao; Jeanne Holden-Wiltse; Timothy R Mosmann; Alexandra M Livingstone; Gabrielle T Belz; Alan S Perelson; Martin S Zand; David J Topham
Journal:  J Immunol       Date:  2011-09-23       Impact factor: 5.422

3.  In vivo ablation of CD11c-positive dendritic cells increases susceptibility to herpes simplex virus type 1 infection and diminishes NK and T-cell responses.

Authors:  Sadik H Kassim; Naveen K Rajasagi; Xiangyi Zhao; Robert Chervenak; Stephen R Jennings
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 4.  Breaking T cell tolerance to beta cell antigens by merocytic dendritic cells.

Authors:  Jonathan D Katz; Edith M Janssen
Journal:  Cell Mol Life Sci       Date:  2011-05-31       Impact factor: 9.261

5.  Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.

Authors:  Olivier Renaudet; Gargi Dasgupta; Ilham Bettahi; Alda Shi; Anthony B Nesburn; Pascal Dumy; Lbachir BenMohamed
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

Review 6.  Listeria monocytogenes: a promising vehicle for neonatal vaccination.

Authors:  Zach Z Liang; Ashley M Sherrid; Anu Wallecha; Tobias R Kollmann
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

7.  Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions.

Authors:  Cecile Le Saout; Sandie Mennechet; Naomi Taylor; Javier Hernandez
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-25       Impact factor: 11.205

8.  The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles.

Authors:  Lane Vc Black; Sarah C Saunderson; Frazer P Coutinho; Morad-Rémy Muhsin-Sharafaldine; Tanvi T Damani; Amy C Dunn; Alexander D McLellan
Journal:  Immunol Cell Biol       Date:  2015-12-09       Impact factor: 5.126

9.  Recruitment of bone marrow CD11b+Gr-1+ cells by polymeric nanoparticles for antigen cross-presentation.

Authors:  Ya-Wun Yang; Wen-Hui Luo
Journal:  Sci Rep       Date:  2017-03-20       Impact factor: 4.379

Review 10.  Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Authors:  Elke S Bergmann-Leitner; Wolfgang W Leitner
Journal:  Vaccines (Basel)       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.